



FORM PTO-1449	APPLICATION NO. 10/580,507	ATTORNEY DOCKET NO. 12332/006
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)	FILING DATE November 26, 2004	GROUP ART UNIT 1657 <del>1644</del>
	FIRST NAMED INVENTOR: Amadeo Parissenti	
EXAMINER NAME: Unknown Dr. K.C. Srivastava		

EXAMINER INITIALS	Cite No.	DOCUMENT NUMBER Number-Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where, Relevant Passages or Relevant Figures Appear
/K.S./	A1	6,664,288 B1	12/16/2003	Pardee et al.	
/K.S./	A2	6,875,745 B2	04/05/2005	Pardee et al.	

#### FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER Number-Kind Code (if known)	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES OR NO
/K.S./	A3	CA 2 369 303 A1	10/19/2000	Canada	A61K 31/35	

EXAMINER INITIAL	NON PATENT LITERATURE DOCUMENTS (Include name of author, title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published.			T
/K.S./	A4	Crown, John, Nonanthracycline Containing Docetaxel-Based Combinations in Metastatic Breast Cancer, The Oncologist 2001:6 (suppl 3): pp. 17-21, AlphaMed Press.		
/K.S./	A5	L. Austin Doyle, et al., A Multidrug Resistance Transporter From Human MCF-7 Breast Cancer Cells, Prac. Natl. Acad. Sci., Vol. 95, pp. 15665-15670, December 1998.		
/K.S./	A6	Douglas D. Ross, et al., Atypical Multidrug Resistance: Breast Cancer Resistance Protein Messenger RNA Expression in Mitochondria-Selected Cell Lines, Journal of the National Cancer Institute, Vol. 91, No. 5, March 3, 1999.		

EXAMINER /Kailash Srivastava/	DATE CONSIDERED 11/19/2008
----------------------------------	-------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 EXAMINER: Dr. K.c. SRIVASTAVA, AU1657	SERIAL NO. <del>Error! Reference source not found.</del> 10/580,507	CASE NO. <del>Error! Reference source not found.</del>
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	FILING DATE <del>Error! Reference source not found.</del>	GROUP ART UNIT 1652 <del>Error! Reference source not found.</del>
(use several sheets if necessary)	APPLICANT(S): <del>Error! Reference source not found.</del>	

EXAMINER INITIAL	NON PATENT LITERATURE DOCUMENTS (Include name of author, title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published.		T
/K.S./	A7	Eswaran Devarajan, et al., Human Breast Cancer MCF-7 Cell Line Contains Inherently Drug-Resistant Subclones With Distinct Genotypic and Phenotypic Features, International Journal of Oncology 20: pp. 913-920, 2002.	
	A8	Erin L. Volk, et al., Methotrexate Cross-Resistance in a Mitoxantrone-selected Multidrug-Resistant MCF-7 Breast Cancer Cell Line Is Attributable to Enhanced Energy-Dependent Drug Efflux, Cancer Research 60: pp. 3514-3521, July 1, 2000.	
	A9	Thomas Litman, et al., The Multidrug-Resistant Phenotype Associated with Overexpression of the New ABC Half-Transporter, MXR (ABCG2), Journal of Cell Science 113, pp. 2011-2021, 2000, Great Britain.	
	A10	Gen Sheng Wu and Zhenhua Ding, Caspase 9 is Required for p53-Dependent Apoptosis and Chemosensitivity in a Human Ovarian Cancer Cell Line, Oncogene 21, pp. 1-8, 2002.	
	A11	Baoqing Guo, et al., Potent Killing of Paclitaxel and Doxorubicin-Resistant Breast Cancer Cells By Calphostin C Accompanied by Cytoplasmic Vacuolization, Breast Cancer Research and Treatment 82: pp. 125-141, 2003, Netherlands.	
	A12	Soo-Jung Park, et al., A P-glycoprotein and MRP1-Independent Doxorubicin-Resistant Variant of the MCF-7 Breast Cancer Cell Line with Defects in Capase-6, -7, -8, -9 and -10 Activation Pathways, Anticancer Research 24: pp. 123-132, 2004.	
	A13	Kostas V. Floros, et al., mRNA Expression Analysis of a Variety of Apoptosis-Related Genes, Including the Novel Gene of the BCL2-Family, BCL2L12, in HL-60 Leukemia Cells After Treatment with Carboplatin and Doxorubicin, Biol. Chem., Vol. 385, pp. 1099-1103, November 2004, Berlin, NY.	
	A14	Ching-Huang Wu, et al., $\beta$ 2-Microglobulin Induces Apoptosis in HL-60 Human Leukemia Cell Line and Its Multidrug Resistant Variants Overexpressing MRP1 but Lacking Bax or Overexpressing P-glycoprotein, Oncogene 20, pp. 7006-7020, 2001.	
/K.S./	A15	Tamara Minko, et al., Preliminary Evaluation of Caspases-Dependent Apoptosis signaling Pathways of Free and HPMA Copolymer-Bound Doxorubicin in Human Ovarian Carcinoma Cells, Journal of Controlled Release 71, pp. 227-237, 2001.	

NOTE: For "T" – please place an "X" if an English translation is being provided to the Patent Office.

EXAMINER /Kailash Srivastava/	DATE CONSIDERED 11/19/2008
-------------------------------	----------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.